Join this webinar to explore reagent lot-to-lot and a standardized approach to tackle this reagent using CLSI’s EP26.
Verification of reagent lot to lot is considered part of good laboratory practices and in many accreditation standards such procedures are required / mandated prior to the use of a new lot of reagent.
As with each new lot of reagent there is always a potential where quality control materials and/or patient sample performance may be impacted. There is a multitude of factors that can affect the performance of a new reagent lot which may include critical changes or updates in the reagent formulation from manufacturers, decreased stability of reagents either due to temperature excursions during transportation and storage or even handling errors to name a few.
As with each new lot of reagent there is always a potential where quality control materials and/or patient sample performance may be impacted. There is a multitude of factors that can affect the performance of a new reagent lot which may include critical changes or updates in the reagent formulation from manufacturers, decreased stability of reagents either due to temperature excursions during transportation and storage or even handling errors to name a few.
What you'll learn
- Understanding the effect of matrix from QC materials during lot-to-lot changes
- Determining what is deemed as a significant change or difference during lot-to-lot evaluation
- Utilizing a standardized and practical approach to document and evaluate reagent lot to lot difference with CLSI’s EP26
- Discuss possible scenarios that may arise when evaluating/performing lot to lot differences using EP26’s protocol and actions to be taken
This webinar is organized in collaboration with the Malaysian Association of Clinical Biochemists (MACB) in an effort to advance online education for medical professionals.
Webinar Details
Date: 5 August 2021 | Thursday
Time: 2.30 pm - 3.30 pm Malaysia time
Location: Microsoft Teams
Time: 2.30 pm - 3.30 pm Malaysia time
Location: Microsoft Teams
For a smoother webinar experience, please click on the link below to download the Microsoft Teams application to your computer or device that you will be using for this session.
Mr Norizhar Bin Mohamed Zakaria
Clinical Quality Manager, Siemens Healthineers, ASEAN. Mr Izhar has over 16+ years of experience in Laboratory Management, Quality Assurance and Compliance, and Auditing (Reference/Vendor Labs). He is also a certified Inspector under the College of American Pathologists (CAP) Laboratory Accreditation Program.
Clinical Quality Manager, Siemens Healthineers, ASEAN. Mr Izhar has over 16+ years of experience in Laboratory Management, Quality Assurance and Compliance, and Auditing (Reference/Vendor Labs). He is also a certified Inspector under the College of American Pathologists (CAP) Laboratory Accreditation Program.
Registration is now closed!
Thank you for all the registrations! To all registrants, please check your inbox or spam email for the webinar link. If you have any questions, feel free to contact us at communications-shsb.my@siemens-healthineers.com.
Nothing on this website or any publication materials of the event (e.g. invitation, brochures, flyer, etc.) creates an obligation on Siemens Healthcare Sdn Bhd or any of its affiliates, including any entities within the Siemens group or any of its or their officers, directors, employees and partners (collectively, the “Siemens Group”) to accept registration(s) for the webinar. Siemens Group reserves the right to accept or reject registration(s) received at its sole discretion and without cause, and any such decisions made shall be final.
Nothing on this website or any publication materials of the event (e.g. invitation, brochures, flyer, etc.) creates an obligation on Siemens Healthcare Sdn Bhd or any of its affiliates, including any entities within the Siemens group or any of its or their officers, directors, employees and partners (collectively, the “Siemens Group”) to accept registration(s) for the webinar. Siemens Group reserves the right to accept or reject registration(s) received at its sole discretion and without cause, and any such decisions made shall be final.